Skip to Content
MilliporeSigma
All Photos(1)

Documents

SML1522

Sigma-Aldrich

Doxofylline

≥98% (HPLC)

Synonym(s):

7-(1,3-Dioxolan-2-ylmethyl)-1,3-dimethylpurine-2,6-dione, 7-(1,3-Dioxolan-2-ylmethyl)theophylline

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C11H14N4O4
CAS Number:
69975-86-6
Molecular Weight:
266.25
MDL number:
MFCD00865218
UNSPSC Code:
12352200
PubChem Substance ID:
329825939
NACRES:
NA.77

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

H2O: 2 mg/mL, clear (warmed)

storage temp.

2-8°C

SMILES string

CN1C2=C(N(CC3OCCO3)C=N2)C(N(C)C1=O)=O

InChI

1S/C11H14N4O4/c1-13-9-8(10(16)14(2)11(13)17)15(6-12-9)5-7-18-3-4-19-7/h6-7H,3-5H2,1-2H3

InChI key

HWXIGFIVGWUZAO-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

Doxofylline is a novel xanthine derivative comprising of dioxolone group.

Application

Doxofylline has been used as a phosphodiesterase (PDE) inhibitor to study its protective effects on lipopolysaccharides (LPS)-induced inflammatory response in human pulmonary bronchial epithelial cells. It has also been used to study its interaction with bovine serum albumin (BSA).

Biochem/physiol Actions

Doxofylline (also known as doxophylline) has antitussive and bronchodilator effects. Doxofylline is used clinically in the treatment of asthma. Doxofylline has similar efficacy to theophylline, but unlike theophylline or other xanthines has little affinity for adenosine receptors and does not produce stimulant effects and has significantly fewer side effects.
Doxofylline acts and as a non-selective phosphodiesterase (PDE) inhibitor and exhibits anti-inflammatory activity. It has the potential to treat chronic obstructive pulmonary disease (COPD).

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Sami Manzoor Margay et al.
Journal of clinical and diagnostic research : JCDR, 9(4), FC05-FC08 (2015-05-30)
Asthma is a non communicable chronic disease prevalent all over the world. Two commonly used methylxanthines, theophylline and doxofylline were compared in the study in stable asthmatic patients at recommended doses by various spirometric lung function tests with forced expiratory
Muhasaparur Ganesan Rajanandh et al.
Clinical therapeutics, 37(2), 418-426 (2015-01-13)
Data comparing various second-line treatments for asthma with subjective and objective assessment are lacking. This study aimed to compare the efficacy and safety of montelukast, doxofylline, and tiotropium with a low-dose budesonide in patients with mild to moderate persistent asthma.
Dushyant Lal et al.
Journal of basic and clinical physiology and pharmacology, 26(5), 443-451 (2015-04-22)
Bronchial asthma and chronic obstructive pulmonary disease (COPD) are the major obstructive disorders that may contribute to the severity in individual patients. The present study was designed to compare the efficacy and safety of theophylline and doxofylline in patients with
R Cirillo et al.
Archives internationales de pharmacodynamie et de therapie, 295, 221-237 (1988-09-01)
In the present study the interaction of doxofylline, a new antiasthmatic drug, with A1- and A2-adenosine receptors of the guinea-pig brain and rat striatum was investigated in comparison with known methylxanthine derivatives. Inhibition studies of N6-cyclohexyl-3H-adenosine (3H-CHA), 1,3-diethyl-8-3H-phenylxanthine (3H-DPX) binding
Sokratis Katsikas et al.
Studies in health technology and informatics, 134, 113-125 (2008-04-01)
The health care sector is quickly exploiting Information and Communication Technologies towards the provision of e-health services. According to recent surveys, one of the most severe restraining factors for the proliferation of e-health is the (lack of) security measures required
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service